Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02194452

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Sue O'Dorisio · Academic / Other
Sex
All
Age
6 Months – 29 Years
Healthy volunteers
Not accepted

Summary

This pilot clinical trial studies gallium Ga 68-edotreotide (68Ga-DOTATOC) positron emission tomography (PET)/computed tomography (CT) in finding brain tumors in younger patients. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT imaging, may help find and diagnose brain tumors.

Detailed description

PRIMARY OBJECTIVES: I. To determine if 68Ga-DOTATOC (gallium Ga 68-edotreotide) PET when combined with magnetic resonance imaging (MRI) will differentiate embryonal tumors such as medulloblastoma and supratentorial primitive neuroectodermal tumor (PNET) from the low and high grade gliomas. II. To determine if 68Ga-DOTATOC PET will aid in the identification of residual tumor post operatively in those patients who were 68Ga-DOTATOC PET positive prior to surgery. OUTLINE: Patients undergo gallium Ga 68-edotreotide PET/CT at baseline and 1-30 days after surgery.

Conditions

Interventions

TypeNameDescription
RADIATIONgallium Ga 68-edotreotideUndergo gallium Ga 68-edotreotide PET/CT
PROCEDUREpositron emission tomographyUndergo gallium Ga 68-edotreotide PET/CT
PROCEDUREcomputed tomographyUndergo gallium Ga 68-edotreotide PET/CT
OTHERlaboratory biomarker analysisCorrelative studies

Timeline

Start date
2013-09-01
Primary completion
2017-03-01
Completion
2017-03-01
First posted
2014-07-18
Last updated
2017-04-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02194452. Inclusion in this directory is not an endorsement.